Medicine anti-corruption efforts to increase the ban of these pharmaceutical companies from Wuxi public hospitals for three years

[China Pharmaceutical network industry trends] on January 3, Wuxi health and Family Planning Commission issued the notice on the establishment of regulations on bad records and "blacklist" of drug, medical consumables and medical equipment suppliers in Wuxi (for Trial Implementation) The notice clearly defines the criteria, bad records and blacklist of violations, and puts forward corresponding punishment measures The notice requires that public medical and health institutions shall not purchase drugs, medical consumables and medical equipment in any name or in any form for pharmaceutical production and distribution enterprises and their agents once listed in the supplier's bad records within two years after the list is published, and the original signed purchase and sale contract shall be terminated immediately For the pharmaceutical production and distribution enterprises listed in the "blacklist" and their agents, it is required that they shall not purchase their drugs, medical consumables and medical equipment in any name or in any form within three years, and the original purchase and sale contract shall be terminated immediately Private medical institutions shall be implemented by reference In fact, there are corresponding measures to punish the drug dealers listed in the "bad record" and "blacklist", and the punishment intensity is different For example, on January 2 this year, the nine departments of Guangdong issued the notice on printing and distributing the key points of special governance work for correcting unhealthy tendencies in the field of pharmaceutical purchase and sale and medical services in 2018, standardizing the production, sale and use of pharmaceutical consumables, and promoting the filing management of pharmaceutical representatives Among them, it is required that the behaviors unrelated to their work, such as using the identity of medical representative to participate in product sales, drug regulation, ticket payment processing, commercial bribery, donation, misleading drug use, distorting curative effect, concealing bad information, etc., shall be included in the "blacklist" and reported to the relevant management department In order to form a situation of dishonesty and impracticability, multi department joint punishment should be carried out for the pharmaceutical enterprises which have serious violations of their pharmaceutical representatives   On January 10, 2017, Shandong provincial health and Family Planning Commission issued the revised Measures for the administration of adverse records of centralized drug purchase in Shandong Province, which requires all drug manufacturing and trading enterprises listed in the adverse records of commercial bribery to cancel the qualification of centralized online purchase of all products of the enterprise; the provincial centralized drug purchase institutions will not accept any online centralized products within two years from the date of announcement of the decision Purchase requisition Public medical and health institutions throughout the province shall not purchase their drugs in any form within two years, and the original purchase and sale contract signed shall be terminated   In addition, as early as 2015, Gansu Province issued the notice of "drug and medical device supervision and management blacklist system (Trial)", which clearly stated that the publicity period of drug and medical device enterprises listed in the "blacklist" is one year During the blacklist period, drug manufacturers and medical institutions should report the safe production, operation and use of drug and medical devices to relevant departments every quarter Status: listed as a key regulatory object, at least once a month for supervision and inspection, tracking the rectification situation; the main person in charge shall not participate in the assessment of excellence within three years In fact, anti-corruption of medicine is a very concerned topic in the industry The author understands that, before that, some experts in the industry pointed out that the quality of drugs, especially fake and inferior drugs, appeared in public medical institutions, and there must be different levels of corruption behind them According to the expert, the flooding of drug kickbacks has not been effectively eradicated The reason is that there are defects in the centralized drug bidding system, which to some extent contributes to the probability of the occurrence of fake and substandard drugs In order to ensure the quality of drugs in medical institutions, social anti-corruption and the construction of clean government in public hospitals are indispensable At present, the anti-corruption of medicine has become more and more powerful, which will be conducive to the stable operation of medical institutions in China and ensure the quality and safety of drugs.